Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 94   

Articles published

LGND 134.88 -0.01 (-0.01%)
price chart
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Given Average Rating of "Buy" by ...
Ligand Pharmaceuticals logo Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has been assigned a consensus rating of “Buy” from the six analysts that are presently covering the firm.
Ligand Pharmaceuticals (NASDAQ:LGND) Sellers Increased By 5.06% Their Shorts  Consumer Eagle
Plus the latest data from Realtor.com on 21 home markets across the US
Ligand Pharmaceuticals Inc. NASDAQ: LGND. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.
Ligand Pharmaceuticals Incorporated versus Momenta Pharmaceuticals Inc Head to ...
Ligand Pharmaceuticals Incorporated has a substantially higher fundamental rating then Momenta Pharmaceuticals Inc which has an impact on the head-to-head comparison.
News Ligand Pharmaceuticals Inc.LGND
News Ligand Pharmaceuticals Inc.LGND. Significant News Only. 14 hours ago; Press Release. Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals.
State Street Corp Has $74940000 Stake in Ligand Pharmaceuticals Inc. (LGND)
Ligand Pharmaceuticals logo State Street Corp increased its stake in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 10.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
Are Analysts Bearish Ligand Pharmaceuticals Inc. (NASDAQ:LGND) After Last Week?  Consumer Eagle
Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 5.5%  Zacks.com
Ligand Pharmaceuticals Inc (NASDAQ:LGND): Continue to Grow
[Market Realist] Ligand Pharmaceuticals Inc (NASDAQ:LGND)(TREND ANALYSIS) was trading at a forward EV-to-EBITDA1 multiple of 17.8x.
BlackRock Institutional Trust Company N.A. Boosts Stake in Ligand ...  Community Financial News
Ligand Pharmaceuticals's Performance Based on EV-to-EBITDA  Market Realist
Ligand Pharmaceuticals Inc. (LGND) Given Buy Rating at Roth Capital
Ligand Pharmaceuticals logo Ligand Pharmaceuticals Inc. (NASDAQ:LGND)'s stock had its “buy” rating reissued by equities researchers at Roth Capital in a research note issued to investors on Tuesday.
Stock in the Spotlight: Ligand Pharmaceuticals Inc
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) reported Fourth quarter earnings on Wednesday, February 10. The company earned $0.66 per share on revenue of $0.65.
Ligand Pharmaceuticals Inc (LGND): David M. Knott of Dorset Management ...
David M. Knott's Dorset Managment, recently filed an amended 13D, with the US SEC, reporting David Knott's resignation from the board of the directors of Ligand Pharmaceuticals Inc (NASDAQ:LGND), for reasons that are unconnected to the company.
Turner Investments LP Increased Ligand Pharmaceuticals INC (NASDAQ:LGND) by $4 ...
Turner Investments Lp increased its stake in Ligand Pharmaceuticals Inc (NASDAQ:LGND) by 205.15% based on its latest 2016Q1 regulatory filing with the SEC.